Loading…
Loading…
LVCLF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LVCLF and 80,000+ other tickers.
See exactly how LVCLF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LVCLF and 80,000+ other tickers.
Algorae Pharmaceuticals Limited, established in 1987 and based in Melbourne, Australia, is a pharmaceutical development company. The firm primarily conducts its research and development in New Zealand, focusing on living cell technologies. Its product pipeline includes several key candidates: AI-116, a novel combination therapy featuring cannabidiol and an existing pharmaceutical ingredient, intended for the treatment of dementia, including Alzheimer's disease; NTCELL, an alginate-coated capsule developed to address Parkinson's disease; and AI-168, another combination drug that combines a…
Quantum computing breakthroughs are accelerating faster than previously expected and could pose a serious near-term threat to cryptocurrency security,...
Algorae Pharmaceuticals Ltd (ASX:1AI, OTC:LVCLF, FRA:LHI0) has completed the prediction-generation phase of a multi-anchor drug combination program using...